Comprehensive Pipeline Analysis for Osteoarthritis Therapeutic Development

DelveInsight's latest analysis of the "Osteoarthritis Pipeline Insights 2025" delivers extensive intelligence on more than 100 organizations and over 110 developmental compounds in the Osteoarthritis therapeutic landscape. The analysis encompasses drug candidate profiles across both clinical and preclinical development phases. Additionally, it includes evaluation of investigational treatments by formulation type, developmental phase, administration method, and molecular classification. The report also identifies dormant pipeline candidates in this therapeutic area.

Maintain competitive advantage with the most current intelligence! Obtain DelveInsight's detailed Osteoarthritis Pipeline Analysis to discover novel treatments, major stakeholders, and upcoming therapeutic directions @ Osteoarthritis Pipeline Outlook Report

Essential Highlights from the Osteoarthritis Pipeline Analysis

In November 2025, Grünenthal GmbH launched a clinical investigation to validate the safety of monoarticular injections or bi-lateral intra-articular injections of RTX-GRT7039 in subjects experiencing pain related to knee osteoarthritis despite standard care treatment. 

In November 2025, Eli Lilly and Company revealed a phase 3 Investigation to Examine the Therapeutic Effectiveness and Safety of Orforglipron Once Daily in Subjects Who Have Obesity or Overweight and Knee Osteoarthritis: A Multicenter, Randomized, Double-Masked, Parallel-Arm, Placebo-Controlled Investigation DelveInsight's Osteoarthritis pipeline analysis reveals a dynamic field with over 100 active organizations advancing more than 110 pipeline candidates for Osteoarthritis therapy. 

The prominent Osteoarthritis Companies include Biosplice Therapeutics, Cynata Therapeutics, Bone Therapeutics S.A, Regeneron Pharmaceuticals, Techfields Pharma, Ampio Pharmaceuticals, Asahi Kasei Pharma, Taiwan Bio Therapeutics, OliPass Corporation, Bioventus, Medipost, LG Chem, ICM Biotech, Cells for Cells SA, GWOXI Stem Cell Applied Technology, UnicoCell Biomed, Magellan Biologicals, Levicept, Arthrogen, Personalized Stem Cells, Peptinov, Orient Europharma, ZYUS Life Sciences, Lubris Biopharma, Saol Therapeutics, Ageless Biotech, Synartro AB, Plakous Therapeutics, Ribomic, Meluha Therapeutics and additional organizations. 

Notable Osteoarthritis Pipeline Therapies include MK0663, Etoricoxib, Diacerein, Celecoxib, RTX-GRT7039, Naproxcinod, Naproxen, LY3857210, LY3556050, LY3016859, Ibuprofen, Voltaren® Gel, Gevokizumab and additional candidates. Understand how the Osteoarthritis therapeutic paradigm is transforming. 

Access DelveInsight's comprehensive Osteoarthritis Pipeline Evaluation for an in-depth examination of promising advances @ Osteoarthritis Clinical Trials and Studies

Osteoarthritis Background

Osteoarthritis (OA) represents the most prevalent form of arthritis. Some individuals refer to it as degenerative joint disease or "wear and tear" arthritis. It manifests most commonly in the hands, hips, and knees. With OA, the cartilage within a joint starts to deteriorate and the underlying bone starts to undergo changes. These alterations typically develop gradually and worsen over time. OA can result in pain, stiffness, and swelling. In certain cases it also results in reduced function and disability; some individuals are no longer capable of performing daily tasks or work. Osteoarthritis is the most prevalent type of arthritis, distinguished by the progressive breakdown of cartilage in joints, resulting in pain, stiffness, and swelling. Symptoms frequently include joint pain that intensifies with activity and diminishes with rest, stiffness lasting under 30 minutes following inactivity, and a sensation of joint instability or looseness. Affected joints may also generate a grinding or creaking sound during movement, and swelling can manifest, particularly following prolonged use.

Osteoarthritis Emerging Drug Profiles

Lorecivivint: Biosplice Therapeutics

Lorecivivint (SM04690) represents a small-molecule CLK/DYRK1A inhibitor that regulates Wnt and inflammatory pathways and is in development as a potential disease-modifying osteoarthritis compound. Vehicle-controlled preclinical evidence suggests that lorecivivint has a dual mechanism of action with three potential effects on joint health: reduction of inflammation, deceleration of cartilage breakdown, and generation of cartilage. The compound is currently advancing through Phase III stage of clinical investigation to treat patients suffering from osteoarthritis.

EP-104IAR: Eupraxia Pharmaceuticals

Eupraxia's primary product candidate, EP-104IAR, is engineered to address the significant unmet medical need and market demand for long-lasting disease relief in multiple indications benefitting from highly localized and prolonged delivery of corticosteroids. The primary indication is for pain relief in knee OA. EP-104IAR is engineered to extend the duration of pain relief with fewer unwanted side effects. It encapsulates a highly potent corticosteroid (fluticasone propionate) within a microns-thin polymer membrane, part of Eupraxia's patented technology platform. Injected into the knee, EP-104IAR is engineered to diffuse the corticosteroid gradually into the knee joint providing local therapeutic concentrations for up to six months. This has the potential dual advantage of providing extended duration of pain relief with fewer systemic side effects. Presently, the compound is in Phase II stage of its clinical investigation for the treatment of OA.

DFV890: Novartis

DFV890 represents a small molecule, NOD-like receptor protein 3 (NLRP3) antagonist being created by Novartis for the treatment of various inflammatory conditions. It is currently undergoing evaluation in several phase I and II clinical investigations, including studies in myeloid diseases, knee osteoarthritis, COVID-19, and cardiovascular disease. DFV890 functions by inhibiting the NLRP3 protein, which serves a key role in the activation of the inflammatory response. Presently, the compound is in Phase II stage of its clinical investigation for the treatment of OA.

4P004: 4P-Pharma

4P004 represents a GLP-1 analog, a potential first-in-class disease modifier compound for osteoarthritis (DMOAD), demonstrating anti-inflammatory, anti-catabolic and anabolic properties. 4P004 was created in collaboration with the team of Prof. Francis Berenbaum and SATT Lutech. 4P004 is owned by 4P-Pharma's SPV – 4Moving Biotech. Presently, the compound is in Phase II stage of its clinical investigation for the treatment of OA.

GNSC 001: Genascence

GNSC-001 represents a genetic medicine – a recombinant adeno-associated viral vector expressing an optimized form of IL-1Ra, a naturally occurring protein that blocks interleukin-1 (IL-1) signaling. IL-1 is considered one of the key mediators involved in the pathogenesis of OA, producing inflammation, joint pain, as well as cartilage destruction. GNSC-001 is engineered to offer long-term, sustained inhibition of IL-1 following a single injection into the affected joint. Presently, the compound is in Phase I stage of its clinical investigation for the treatment of OA.

The Osteoarthritis Pipeline Analysis Delivers Intelligence Into

The analysis delivers comprehensive intelligence about organizations developing treatments for Osteoarthritis with aggregated therapies developed by each organization for the same indication. It evaluates various therapeutic candidates categorized into early-phase, mid-phase, and late-phase development for Osteoarthritis Treatment. Osteoarthritis Companies are engaged in targeted therapeutic development with corresponding active and inactive (dormant or terminated) projects. Osteoarthritis Drugs in development classified by developmental phase, administration route, target receptor, monotherapy or combination therapy, various mechanisms of action, and molecular classification. Comprehensive analysis of partnerships (company-company partnerships and company-academia partnerships), licensing agreements and financial arrangements for future progression of the Osteoarthritis market. Obtain a comprehensive analysis of the most recent innovations in the Osteoarthritis pipeline. Discover DelveInsight's expert-driven analysis today! @ Osteoarthritis Unmet Needs

Osteoarthritis Companies

Biosplice Therapeutics, Cynata Therapeutics, Bone Therapeutics S.A, Regeneron Pharmaceuticals, Techfields Pharma, Ampio Pharmaceuticals, Asahi Kasei Pharma, Taiwan Bio Therapeutics, OliPass Corporation, Bioventus, Medipost, LG Chem, ICM Biotech, Cells for Cells SA, GWOXI Stem Cell Applied Technology, UnicoCell Biomed, Magellan Biologicals, Levicept, Arthrogen, Personalized Stem Cells, Peptinov, Orient Europharma, ZYUS Life Sciences, Lubris Biopharma, Saol Therapeutics, Ageless Biotech, Synartro AB, Plakous Therapeutics, Ribomic, Meluha Therapeutics and additional organizations.

Osteoarthritis Pipeline Analysis Delivers Therapeutic Evaluation

The pipeline analysis delivers therapeutic evaluation of developmental drugs by Administration Route. Products have been organized under various administration routes including:

Oral Intravenous Subcutaneous Parenteral Topical

Osteoarthritis Products Organized by Molecular Classification

Products have been organized under various molecular types including:

Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy

Download DelveInsight's current analysis to obtain strategic intelligence into emerging Osteoarthritis Therapies and significant Developments @ Osteoarthritis Market Drivers and Barriers, and Future Perspectives

Parameters of the Osteoarthritis Pipeline Analysis

Coverage- Global 

Osteoarthritis Companies- Biosplice Therapeutics, Cynata Therapeutics, Bone Therapeutics S.A, Regeneron Pharmaceuticals, Techfields Pharma, Ampio Pharmaceuticals, Asahi Kasei Pharma, Taiwan Bio Therapeutics, OliPass Corporation, Bioventus, Medipost, LG Chem, ICM Biotech, Cells for Cells SA, GWOXI Stem Cell Applied Technology, UnicoCell Biomed, Magellan Biologicals, Levicept, Arthrogen, Personalized Stem Cells, Peptinov, Orient Europharma, ZYUS Life Sciences, Lubris Biopharma, Saol Therapeutics, Ageless Biotech, Synartro AB, Plakous Therapeutics, Ribomic, Meluha Therapeutics and additional organizations. 

Osteoarthritis Pipeline Therapies- MK0663, Etoricoxib, Diacerein, Celecoxib, RTX-GRT7039, Naproxcinod, Naproxen, LY3857210, LY3556050, LY3016859, Ibuprofen, Voltaren® Gel, Gevokizumab and additional candidates. 

Osteoarthritis Therapeutic Evaluation by Product Type: Mono, Combination, Mono/Combination 

Osteoarthritis Therapeutic Evaluation by Clinical Phases: Discovery, Pre-clinical, Phase I, Phase II, Phase III 

Which organizations are leading the advancement in Osteoarthritis drug development? Discover details in DelveInsight's exclusive Osteoarthritis Pipeline Analysis—access it now! @ Osteoarthritis Emerging Drugs and Major Companies

Contents Overview

1. Introduction

2. Executive Summary

3. Osteoarthritis: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Osteoarthritis– DelveInsight’s Analytical Perspective

7. Late Stage Products (Phase III)

8. Lorecivivint: Biosplice Therapeutics

9. Mid Stage Products (Phase II)

10. EP-104IAR: Eupraxia Pharmaceuticals

11. Early Stage Products (Phase I)

12. GNSC 001: Genascence

13. Preclinical and Discovery Stage Products

14. Drug name: Company name

15. Inactive Products

16. Osteoarthritis Key Companies

17. Osteoarthritis Key Products

18. Osteoarthritis- Unmet Needs

19. Osteoarthritis- Market Drivers and Barriers

20. Osteoarthritis- Future Perspectives and Conclusion

21. Osteoarthritis Analyst Views

22. Osteoarthritis Key Companies

23. Appendix

About Us

DelveInsight operates as a premier healthcare-focused market research and consulting organization that delivers clients superior market intelligence and analysis to facilitate informed business strategies. Supported by a team of seasoned industry specialists and profound expertise in the life sciences and healthcare domains, we provide tailored research solutions and intelligence to clients worldwide. Connect with us to obtain high-quality, precise, and real-time intelligence to maintain competitive advantage in the growth trajectory.

Contact Us

Kanishk

kkumar@delveinsight.com